- Centronuclear myopathies (CNMs) are rare congenital muscle disorders that impair muscle strength and function due to abnormal positioning of cell nuclei. Increasing regulatory support for orphan drugs and early diagnosis through newborn screening are significantly enhancing treatment accessibility and awareness
- The demand for these microscopes is significantly driven by the increasing prevalence of age-related eye conditions and advancements in surgical techniques
- North America is expected to dominate the Centronuclear Myopathies Drugs market due to early access to clinical trials and regulatory approvals
- Asia-Pacific is expected to be the fastest growing region in the Centronuclear Myopathies Drug market during the forecast period due to growth through collaborative research initiatives
- Antisense oligonucleotides and enzyme replacement therapies are gaining traction as the standard of care for certain CNM subtypes, with several candidates in late-phase clinical development
